SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ADVENTRX Pharmaceuticals Inc (Anx)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: patrickp who wrote (237)8/22/2007 5:48:26 PM
From: Keith FeralRead Replies (2) of 418
 
Here is the timeline I see emerging.

Company is back in discussions with marketing partners right now to seal the deal. After Labor Day, they hit the road to gain institutional support for the deal and make some friends. The data will come out in first week of October. Once the data is out, the stock price should pop allowing the company to force the conversion of warrants. That's another $20 million that we shouldn't forget about.

From there, we get the announcements about the partnership deals for Vinorelbine or Cofactor. The company files the NDA for Vinorelbine, launches a IND for Thiovir and Docetaxel, and starts working like crazy to finish phase 3 enrollment for Cofactor in the US and Europe as a single trial.

That's the way I hope things unfold this fall. I don't see too much getting started until after Labor Day.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News